Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.
Tissue-based determination of Ki-67, a marker of cellular proliferation, has shown prognostic value in solid tumors and hematological malignancies. We developed and validated an electrochemiluminescence-based method for sensitive measurement of circulating Ki-67 in plasma (cKi-67). This assay demonstrated significantly higher levels of cKi-67 in patients with newly diagnosed acute lymphoblastic leukemia (ALL) (n=27; median, 762; range, 0-4574U/100 microL) than in healthy control subjects (n=114; median, 399; range, 36-2830U/100 microL). Moreover, elevated plasma cKi-67 was associated with significantly shorter survival in ALL patients (P=0.05). These findings suggest that Ki-67 can be detected in circulation and has potential for use as a biomarker for predicting clinical behavior in ALL.
Bruey
Jean-Marie
JM
Hematology, Quest Diagnostics Nichols Institute, Building A, Hematopathology/Oncology R&D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States. jeanmarie.x.bruey@questdiagnostics.com
Kantarjian
Hagop
H
Estrov
Zeev
Z
Zhang
Zhong
Z
Ma
Wanlong
W
Albitar
Ferras
F
Abdool
Adam
A
Thomas
Deborah
D
Yeh
Chenhsiung
C
O'Brien
Susan
S
Albitar
Maher
M
D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000592:standards; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood*; D008163:Luminescent Measurements / Q000379:methods / Q000592:standards; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen
Scand J Urol Nephrol. 2009;43(1):12-8
18949633
Neoplasma. 2005;52(5):420-4
16151588
Leuk Res. 2003 Oct;27(10):903-8
12860010
J Surg Oncol. 1998 Jan;67(1):33-7
9457254
Blood. 2003 Apr 1;101(7):2507-13
12446458
Cancer Lett. 1997 May 19;115(2):229-34
9149129
J Natl Cancer Inst. 2007 Jul 4;99(13):1053; author reply 1053-4
17596578
Proc Natl Acad Sci U S A. 1985 May;82(10):3262-6
2860667
Oncol Rep. 1999 Sep-Oct;6(5):1117-22
10425312
Cancer Gene Ther. 2009 Jan;16(1):20-32
18690204
J Cell Physiol. 2000 Mar;182(3):311-22
10653597
Cancer Sci. 2008 Aug;99(8):1564-9
18754867
N Engl J Med. 2004 Apr 8;350(15):1535-48
15071128
Blood. 2004 Apr 1;103(7):2799-801
14576069
Exp Cell Res. 2000 Jun 15;257(2):231-7
10837136
J Natl Cancer Inst. 1987 Dec;79(6):1333-40
3320449
Rocz Akad Med Bialymst. 2002;47:262-9
12533969
Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61
15182827
Histopathology. 2007 Oct;51(4):491-8
17711446
J Immunol. 1984 Oct;133(4):1710-5
6206131
Expert Rev Mol Diagn. 2007 Sep;7(5):615-23
17892367
J Clin Oncol. 2005 Oct 1;23(28):7212-20
16192605
Histopathology. 2002 Jan;40(1):2-11
11903593
Breast Cancer Res Treat. 2009 Jul;116(1):53-68
18592370
Br J Haematol. 2003 Dec;123(5):850-7
14632776
Cancer. 2004 Sep 1;101(5):999-1008
15329909
FASEB J. 2003 Mar;17(3):333-40
12631573
Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77
17508214